Tetraphase

Tetraphase Pharmaceuticals Inc. of Newton, Mass., has secured $10.04 million of a $25.1 million Series A convertible participating preferred stock financing. MediPhase Venture Partners led the deal, with other backers including Skyline Ventures, Fidelity BioSciences, Flagship Ventures and CMEA Ventures. This item was first reported by PE Week Wire in August, with VentureWire today adding that MediPhase had taken the lead.